Filing Details

Accession Number:
0000899243-20-026193
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-23 19:11:31
Reporting Period:
2020-09-21
Accepted Time:
2020-09-23 19:11:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776851 Vida Ventures Ii, Llc 40 Broad Street, Suite 201
Boston MA 02109
No No Yes No
1781930 Vida Ventures Ii-A, Llc 40 Broad Street, Suite 201
Boston MA 02109
No No Yes No
1824569 Vv Manager Ii, Llc 40 Broad Street, Suite 201
Boston MA 02109
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-21 2,087,130 $0.00 2,087,130 No 4 C Indirect See footnotes
Common Stock Acquisiton 2020-09-21 792,995 $19.00 2,880,125 No 4 P Indirect See footnotes
Common Stock Acquisiton 2020-09-21 57,916 $0.00 57,916 No 4 C Indirect See footnote
Common Stock Acquisiton 2020-09-21 22,005 $19.00 79,921 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2020-09-21 6,922,803 $0.00 2,087,130 $0.00
Common Stock Series B Preferred Stock Disposition 2020-09-21 192,102 $0.00 57,916 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  2. The shares are held directly by Vida Ventures II, LLC ("Vida II"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the "Management Committee") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the "Investment Committee").
  3. (Continued from Footnote 2) Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
  4. The shares are held directly by Vida Ventures II-A, LLC ("Vida II-A"). VV Manager II is the manager of Vida II-A. Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.